The FDA has authorized Abbott’s Libre Duo 10 Day, the first system approved in the U.S. to continuously monitor both glucose and ketones with a single wearable sensor. Abbott developed the device primarily to warn people with diabetes of rising ketones that could signal diabetic ketoacidosis (DKA). But ketones are not inherently pathological. In nutritional and therapeutic ketosis, elevated ketones accompanied by relatively low glucose represent a very different metabolic state.

That distinction makes the new technology particularly interesting in light of recent work from Thomas Seyfried and colleagues proposing the Glucose Ketone Index (GKI) as a way to quantify metabolic state by considering glucose and ketones together. Until now, tracking GKI has generally required repeated finger-stick measurements. Although Abbott’s device is not designed or approved to calculate GKI, continuously measuring both glucose and ketones could eventually make it possible to follow GKI throughout the day—providing a much richer picture of how diet, exercise, fasting, and other interventions affect metabolic state.

https://www.yahoo.com/news/science/articles/fda-approves-abbott-libre-duo-112628041.html